Registry collecting data on patients with myasthenia gravis, a rare autoimmune neuromuscular disorder
start of the project: January 2016
Myasthenia gravis is an autoimmune disorder in which antibodies form against acetylcholine nicotinic postsynaptic receptors at the neuromuscular junction of skeletal muscles, resulting into a fluctuating weakness of these muscles. Extraocular muscles and muscles of the eyelid are affected most frequently, leading to diplopia and ptosis. Other typical symptoms involve disorders of articulation, swallowing, chewing, and several others. The symptoms typically occur in the evenings or after an exertion, and therefore have a fluctuating character. Antibodies against the acetylcholine receptor are present in about 85% of patients. Causal treatment of myasthenia gravis involves the administration of immunosuppressants or immunomodulators (corticosteroids, azathioprine, ciclosporin, IVIG), suppressing the autoimmune process. Cholinesterase inhibitors can be used as supportive therapy, increasing the availability of acetylcholine molecules.
Primary objective of the project:
Secondary objectives of the project:
Other important information: